B-cell acute lymphoblastic leukemia · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Nilotinib monotherapy Variant #01 | BCR::ABL1 | R 27 206 | 28d | — | — | — | — | — |
Dasatinib, Vincristine, Prednisone Variant #01 | BCR::ABL1 | R 13 102 | 28d | — | — | — | — | — |
Dasatinib monotherapy Variant #01 | BCR::ABL1 | R 12 899 | 28d | — | — | — | — | — |
POMP Variant #01 | — | R 8 725 | 30d | — | — | — | — | — |
Imatinib, Vincristine, Prednisone Variant #01 | BCR::ABL1 | R 8 607 | 28d | — | — | — | — | — |
Mercaptopurine and Methotrexate Variant #05 | — | R 2 336 | 14d | — | — | — | — | — |
Mercaptopurine, Methotrexate, Vincristine, Dexamethasone N/A - intrathecal component | — | R 1 055 | 84d | — | — | — | — | — |
7 of 7 regimens shown